Literature DB >> 20884155

An outbreak case of Clostridium difficile-associated diarrhea among elderly inpatients of an intensive care unit of a tertiary hospital in Rio de Janeiro, Brazil.

Ilana Teruszkin Balassiano1, Joaquim Dos Santos-Filho, Márcia Pinto Barros de Oliveira, Maria Catarina Ramos, Andre M Japiassu, Alessandro Mendonça Dos Reis, Jon S Brazier, Eliane de Oliveira Ferreira, Regina Maria Cavalcanti Pilotto Domingues.   

Abstract

The aim of this study was to investigate Clostridium difficile-associated diarrhea (CDAD) in an intensive care unit (ICU) of a tertiary hospital in Rio de Janeiro, Brazil, and to characterize epidemiologically C. difficile strains obtained from an outbreak of CDAD. Within almost a 4-year surveillance period, CDAD incidence was determined for the first time in Brazil, and a 3-fold increase was observed in the average rate of CDAD, featuring an outbreak. About 80% of the patients were over 65 years. The main antibiotic that could be probably associated to CDAD was piperacillin/tazobactam. Four toxigenic strains were isolated, 3 from stools and 1 from environmental samples. They were all resistant to clindamycin and fluoroquinolones. Fingerprinting analysis revealed their distribution between 2 different polymerase chain reaction ribotypes, with one of them being exclusively found in Brazil. It was possible to detect cross-infection and environmental contamination in the ICU. Our results highlight the importance of a continuous CDAD surveillance in the hospitals, especially when a risk group is exposed.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884155     DOI: 10.1016/j.diagmicrobio.2010.07.017

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Binding of the extracellular matrix laminin-1 to Clostridioides difficile strains.

Authors:  Mayara Gil de Castro Santos; Camilla Nunes Dos Reis Trindade; Rossiane Cláudia Vommaro; Regina Maria Calvalcanti Pilotto Domingues; Eliane de Oliveira Ferreira
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-06-17       Impact factor: 2.747

Review 2.  Clostridium difficile Infection.

Authors:  Jae Hyun Shin; Esteban Chaves-Olarte; Cirle A Warren
Journal:  Microbiol Spectr       Date:  2016-06

3.  When is an outbreak an outbreak? Using literature and discharge data to define Clostridioides difficile incidence changes referred to as outbreaks.

Authors:  C C Cohen; G Azhar; L Muggy
Journal:  J Hosp Infect       Date:  2020-03-20       Impact factor: 3.926

4.  Epidemiology of Clostridium difficile infection: results of a hospital-based study in Krakow, Poland.

Authors:  J Czepiel; J Kędzierska; G Biesiada; M Birczyńska; W Perucki; P Nowak; A Garlicki
Journal:  Epidemiol Infect       Date:  2015-04-10       Impact factor: 4.434

5.  Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit.

Authors:  H Habayeb; B Sajin; K Patel; C Grundy; A Al-Dujaili; S Van de Velde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

6.  Prevalence and Clinical Outcomes of Clostridium difficile Infection in the Intensive Care Unit: A Systematic Review and Meta-Analysis.

Authors:  Styliani Karanika; Suresh Paudel; Fainareti N Zervou; Christos Grigoras; Ioannis M Zacharioudakis; Eleftherios Mylonakis
Journal:  Open Forum Infect Dis       Date:  2015-12-01       Impact factor: 3.835

7.  Clostridium difficile ribotypes in humans and animals in Brazil.

Authors:  Rodrigo Otávio Silveira Silva; Maja Rupnik; Amanda Nádia Diniz; Eduardo Garcia Vilela; Francisco Carlos Faria Lobato
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-12-11       Impact factor: 2.743

8.  A worldwide systematic review and meta-analysis of bacteria related to antibiotic-associated diarrhea in hospitalized patients.

Authors:  Hamid Motamedi; Matin Fathollahi; Ramin Abiri; Sepide Kadivarian; Mosayeb Rostamian; Amirhooshang Alvandi
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.